Atrium Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell RNA and other ETFs, options, and stocks.

About RNA

Atrium Therapeutics, Inc. operates as a biopharmaceutical company that provides RNA therapeutics services to the heart to transform the standard of care for people living with cardiomyopathies. Its products pipeline includes two lead development candidates: ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy, both conditions are severe, life-threatening, rare autosomal dominant progressive cardiomyopathies with no approved treatment options and high unmet need. 

CEO
Kathleen Gallagher
CEOKathleen Gallagher
Employees
Employees
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
Founded
Employees
Employees

RNA Key Statistics

Market cap
216.90M
Market cap216.90M
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
201.27K
Average volume201.27K
High today
$13.12
High today$13.12
Low today
$12.29
Low today$12.29
Open price
$12.83
Open price$12.83
Volume
294.10K
Volume294.10K
52 Week high
$16.77
52 Week high$16.77
52 Week low
$11.40
52 Week low$11.40

Stock Snapshot

The current Atrium Therapeutics(RNA) stock price is $12.66, with a market capitalization of 216.9M.

As of 2026-06-21, Atrium Therapeutics(RNA) stock has fluctuated between $12.29 and $13.12. The current price stands at $12.66, placing the stock +3.0% above today's low and -3.5% off the high.

The Atrium Therapeutics(RNA)'s current trading volume is 294.1K, compared to an average daily volume of 201.27K.

During the past year, Atrium Therapeutics(RNA) stock moved between $11.40 at its lowest and $16.77 at its peak.

During the past year, Atrium Therapeutics(RNA) stock moved between $11.40 at its lowest and $16.77 at its peak.

RNA News

TipRanks 4d
Atrium Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Atrium Therapeutics (RNA) with an Overweight rating and $25 price target Atrium’s RNA delivery programs using antibody-o...

People also own

Based on the portfolios of people who own RNA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.